Gilead Sciences, Inc. (NASDAQ: GILD), a major player in the pharmaceutical industry in the U.S., has announced that it has received an additional indication approval from China’s National Medical Products Administration (NMPA) for its anti-viral drug Descovy (emtricitabine, tenofovir alafenamide fumarate). The NMPA has granted approval for the use of Descovy as a pre-exposure prophylaxis (PrEP) in adults and adolescents who weigh at least 35kg and are at risk of human immunodeficiency virus type 1 (HIV-1) infection. This new indication aims to mitigate the risk of HIV-1 infection attributed to high-risk sexual behavior.
The fixed dose combination product comprises two molecules that are both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs). Previously, Descovy had been approved by the NMPA for the treatment of HIV-1 infections in adults and adolescents aged 12 years and above who weigh at least 35kg, to be used in combination with other antiretroviral drugs.- Flcube.com
